Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Completed · Phase 4

Conditions studied: Chronic Phase Chronic Myeloid Leukemia

In brief

This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.

Key facts

Study ID

NCT01660906

Run by

Bristol-Myers Squibb

People needed

39

Starts

2012-12-01

Expected to finish

2015-10-01

Last updated by the study team

2016-11-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with CML-CP patients achieving an optimal response to imatinib treatment with Grade 1 or 2 non-hematologic adverse events persisting for at least 2 months or recurring at least 3 times in the preceding 12 months, despite best supportive care
• Men and women with Chronic Myeloid Leukemia- Chronic Phase (CML-CP) Ph+ ≥ age 18
• Daily Eastern Co-Operative Group (ECOG) performance status = 0 - 2
• Patient willing and able to give informed consent
• Life expectancy > 6 months
• Adequate renal function
• Adequate hepatic function

You may not qualify if…

• Patients who are pregnant or breast feeding
• Men whose partner is unwilling to avoid pregnancy.
• Previous treatment with any other tyrosine-kinase inhibitor (TKI), except for imatinib
• Current grade 3 or 4 imatinib related adverse event
• Prior documented T315I mutation
• Prior diagnosis of accelerated phase or blast crisis CML
• Previous loss of complete hematologic response (CHR) or major cytogenetic response (MCyR) on imatinib
• Concurrent medical condition of uncontrolled infection, cardiovascular diseases of cardiac failure, congenital long QT syndrome, ventricular arrhythmias, prolonged QT interval, second or third degree heart block, uncontrolled angina, myocardial infarction (MI) in the last 6 months, uncontrolled hypertension, pulmonary arterial hypertension, pleural or pericardial effusions, or history of bleeding disorder

Where it is running

• Pacific Cancer Medical Center — Anaheim, California, United States
• Cancer Center Of Central Connecticut — Southington, Connecticut, United States
• St. Agnes Healthcare, Inc. — Baltimore, Maryland, United States
• Promedica Hematology & Oncology Assoicates — Sylvania, Ohio, United States
• The University Of Texas Md Anderson Cancer Center — Houston, Texas, United States
• Local Institution — Créteil, France
• Local Institution — Lille, France
• Local Institution — Pierre-Bénite, France
• Local Institution — Pringy, France
• Local Institution — Vandœuvre-lès-Nancy, France
• Local Institution — Cologne, Germany
• Local Institution — Jena, Germany
• Local Institution — Lübeck, Germany
• Local Institution — Mannheim, Germany
• Local Institution — Rostock, Germany
• Local Institution — Catania, Italy
• Local Institution — Florence, Italy
• Local Institution — Naples, Italy
• Local Institution — Roma, Italy
• Local Institution — Roma, Italy
• Local Institution — Torino, Italy
• Local Institution — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.